<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230619</url>
  </required_header>
  <id_info>
    <org_study_id>RVH002</org_study_id>
    <secondary_id>2010-022113-25</secondary_id>
    <nct_id>NCT01230619</nct_id>
  </id_info>
  <brief_title>Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis</brief_title>
  <official_title>A Two Day, Randomised, Single Blind, Parallel Group Trial of Repeat Doses of Intranasal RV568 in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respivert Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respivert Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic&#xD;
      rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568&#xD;
      ameliorates the nasal symptoms to low doses of grass pollen in healthy subjects with seasonal&#xD;
      allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total nasal symptom score (TNSS)</measure>
    <time_frame>2 day treatment period</time_frame>
    <description>Nasal congestion, rhinorrhoea, nasal itching and sneezing will be scored on a categorical scale from 0 to 3. Individual scores will be summed to produce the TNSS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eye symptom score</measure>
    <time_frame>2 day treatment period</time_frame>
    <description>Watery eyes, itchy eyes, red eyes will be scored on a categorical scale of 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global symptom score</measure>
    <time_frame>2 day treatment period</time_frame>
    <description>Sum of symptom scores; TNSS, Eye symptom score, Other symptom score,(comprising congestion, rhinorrhoea, nasal itching, sneezing, watery eyes, itchy eyes, red eyes, cough, itchy throat and itchy ears) will be scored categorically from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal airflow resistance</measure>
    <time_frame>2 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>3 weeks</time_frame>
    <description>Spirometry, 12-lead ECG, laboratory assessments and adverse event assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>RV568 treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV568</intervention_name>
    <description>RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2</description>
    <arm_group_label>RV568 treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2</description>
    <arm_group_label>Placebo treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is healthy&#xD;
&#xD;
          -  History of seasonal allergic rhinitis&#xD;
&#xD;
          -  Male aged between 18 and 55 years&#xD;
&#xD;
          -  Body weight &gt;/= 50 kg with BMI in range 19 - 29 kg/m2 (inclusive)&#xD;
&#xD;
          -  Exhibits a moderate response to 4 hour exposure to grass pollen in the challenge&#xD;
             chamber with a total nasal symptom score (TNSS) of &gt;/= 6&#xD;
&#xD;
          -  Positive skin prick test (wheal &gt;/= 4 mm) for grass pollen&#xD;
&#xD;
          -  Positive total IgE result (RAST class &gt;/= 2) for grass pollen&#xD;
&#xD;
          -  Current non-smoker who has not used tobacco in the past 6 months with a pack history&#xD;
             of &lt;/= 10 pack years&#xD;
&#xD;
          -  Baseline FEV1 &gt;/= 80% and FEV1/FVC &gt;/= 70% of predicted values&#xD;
&#xD;
          -  No conditions or factors that may preclude subjects ability to remain in the challenge&#xD;
             chamber for a period of 6 hours&#xD;
&#xD;
          -  capable of giving informed consent and is compliant with protocol requirements&#xD;
&#xD;
          -  available to complete all study measurements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  structural nasal abnormalities or nasal polyps, history of frequent nosebleeds, recent&#xD;
             nasal surgery or recent (within 3 weeks) or ongoing upper respiratory tract infection&#xD;
&#xD;
          -  history of drug allergy&#xD;
&#xD;
          -  participation in another clinical trial or has participated in a study using an NCE&#xD;
             within the previous 3 months, or any clinical study within 1 month&#xD;
&#xD;
          -  taking regular (or a course of) medication whether prescribed or not, including&#xD;
             steroids, vitamins, macrolides, anti-fungal agents and herbal remedies. Paracetamol&#xD;
             (&lt;/= 2g / day) and occasional short acting beta agonists are permitted&#xD;
&#xD;
          -  use of oral, injectable or dermal steroids within 5 weeks or intranasal and/or inhaled&#xD;
             steroids within 1 week of the screening visit&#xD;
&#xD;
          -  past or present disease, which as judged by the investigator, may affect the outcome&#xD;
             of the study&#xD;
&#xD;
          -  regular consumption of &gt; 21 units alcohol per week&#xD;
&#xD;
          -  infected with Hepatitis B, Hepatitis C, or HIV virus&#xD;
&#xD;
          -  current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  positive test for drugs of abuse or alcohol at screening&#xD;
&#xD;
          -  previously known allergy to any of the active or inactive ingredients in the study&#xD;
             medication&#xD;
&#xD;
          -  mentally or legally incapacitated&#xD;
&#xD;
          -  any other reason that the investigator considers makes the subject unsuitable to&#xD;
             participate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Dr Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Allergy Research - Vienna Challenge Chamber</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Allergy Research, Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>December 3, 2010</last_update_submitted>
  <last_update_submitted_qc>December 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Garth Rapeport</name_title>
    <organization>Respivert Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

